drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00476 | DB01191 | 109 | 1,039 | [
"DDInter608",
"DDInter518"
] | Duloxetine | Dexfenfluramine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
109,
25,
1039
]
],
[
[
109,
40,
181
],
[
181,
1,
1039
]
],
[
[
109,
6,
6112
],
[
6112,
45,
1039
]
],
[
[
109,
24,
1045
],
[
1045,
... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Duloxetine",
"{u} (Compound) resembles {v} (Compound)",
"Cinacalcet"
],
[
"Cinacalcet",
"{u} (Compound) resembles {v} (Com... | Duloxetine (Compound) resembles Cinacalcet (Compound) and Cinacalcet (Compound) resembles Dexfenfluramine (Compound)
Duloxetine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dexfenfluramine (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib a... |
DB01278 | DB01285 | 1,021 | 708 | [
"DDInter1506",
"DDInter445"
] | Pramlintide | Corticotropin | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
1021,
24,
708
]
],
[
[
1021,
63,
1052
],
[
1052,
23,
708
]
],
[
[
1021,
63,
245
],
[
245,
24,
708
]
],
[
[
1021,
24,
1254
],
[
1254,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glim... |
DB00529 | DB00631 | 789 | 372 | [
"DDInter779",
"DDInter405"
] | Foscarnet | Clofarabine | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
789,
24,
372
]
],
[
[
789,
21,
28882
],
[
28882,
60,
372
]
],
[
[
789,
24,
927
],
[
927,
63,
372
]
],
[
[
789,
25,
361
],
[
361,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",... | Foscarnet (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Clofarabine (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerba... |
DB00533 | DB00798 | 1,416 | 1,132 | [
"DDInter1613",
"DDInter815"
] | Rofecoxib | Gentamicin | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Moderate | 1 | [
[
[
1416,
24,
1132
]
],
[
[
1416,
63,
1555
],
[
1555,
24,
1132
]
],
[
[
1416,
24,
1662
],
[
1662,
63,
1132
]
],
[
[
1416,
24,
372
],
[
372... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and... |
DB01073 | DB08871 | 1,488 | 36 | [
"DDInter745",
"DDInter666"
] | Fludarabine | Eribulin | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
1488,
24,
36
]
],
[
[
1488,
24,
221
],
[
221,
63,
36
]
],
[
[
1488,
63,
563
],
[
563,
24,
36
]
],
[
[
1488,
24,
973
],
[
973,
24... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Fludarabine may cause a moder... |
DB01592 | DB11248 | 1,596 | 1,193 | [
"DDInter975",
"DDInter1965"
] | Iron | Zinc gluconate | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Minor | 0 | [
[
[
1596,
23,
1193
]
],
[
[
1596,
62,
1096
],
[
1096,
23,
1193
]
],
[
[
1596,
24,
29
],
[
29,
23,
1193
]
],
[
[
1596,
63,
246
],
[
246,
... | [
[
[
"Iron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Iron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"... | Iron may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Triethylenetetramin... |
DB00060 | DB06603 | 912 | 39 | [
"DDInter947",
"DDInter1387"
] | Interferon beta-1a | Panobinostat | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
912,
24,
39
]
],
[
[
912,
24,
1247
],
[
1247,
23,
39
]
],
[
[
912,
24,
1627
],
[
1627,
63,
39
]
],
[
[
912,
63,
1560
],
[
1560,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfameth... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when take... |
DB00619 | DB11718 | 1,419 | 927 | [
"DDInter909",
"DDInter640"
] | Imatinib | Encorafenib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
1419,
25,
927
]
],
[
[
1419,
63,
216
],
[
216,
24,
927
]
],
[
[
1419,
24,
372
],
[
372,
24,
927
]
],
[
[
1419,
25,
484
],
[
484,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorprom... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and ... |
DB11952 | DB12267 | 800 | 1,476 | [
"DDInter612",
"DDInter233"
] | Duvelisib | Brigatinib | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
800,
24,
1476
]
],
[
[
800,
64,
1135
],
[
1135,
23,
1476
]
],
[
[
800,
63,
168
],
[
168,
23,
1476
]
],
[
[
800,
63,
629
],
[
629,
... | [
[
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Duvelisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Duvelisib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a mino... |
DB00539 | DB09080 | 11 | 144 | [
"DDInter1837",
"DDInter1331"
] | Toremifene | Olodaterol | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
11,
24,
144
]
],
[
[
11,
23,
1247
],
[
1247,
23,
144
]
],
[
[
11,
25,
956
],
[
956,
24,
144
]
],
[
[
11,
24,
504
],
[
504,
24,
... | [
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Toremifene may lead to a major life threatening interaction when taken with Norfloxacin and Norfloxacin ... |
DB08865 | DB12834 | 1,593 | 148 | [
"DDInter448",
"DDInter1649"
] | Crizotinib | Secnidazole | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
1593,
24,
148
]
],
[
[
1593,
24,
1480
],
[
1480,
24,
148
]
],
[
[
1593,
63,
1191
],
[
1191,
24,
148
]
],
[
[
1593,
64,
1554
],
[
1554,... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa ma... |
DB00398 | DB11978 | 79 | 124 | [
"DDInter1702",
"DDInter822"
] | Sorafenib | Glasdegib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
79,
24,
124
]
],
[
[
79,
23,
1135
],
[
1135,
23,
124
]
],
[
[
79,
24,
327
],
[
327,
24,
124
]
],
[
[
79,
24,
1032
],
[
1032,
63,... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Sorafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"N... | Sorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may ... |
DB00909 | DB14723 | 306 | 159 | [
"DDInter1971",
"DDInter1026"
] | Zonisamide | Larotrectinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
306,
24,
159
]
],
[
[
306,
24,
222
],
[
222,
23,
159
]
],
[
[
306,
24,
98
],
[
98,
24,
159
]
],
[
[
306,
63,
597
],
[
597,
24,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somat... |
DB00196 | DB00831 | 600 | 1,178 | [
"DDInter743",
"DDInter1866"
] | Fluconazole | Trifluoperazine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
600,
24,
1178
]
],
[
[
600,
25,
695
],
[
695,
40,
1178
]
],
[
[
600,
24,
851
],
[
851,
40,
1178
]
],
[
[
600,
24,
9
],
[
9,
1,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Cloz... | Fluconazole may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Trifluoperazine (Compound)
Fluco... |
DB00363 | DB09080 | 695 | 144 | [
"DDInter419",
"DDInter1331"
] | Clozapine | Olodaterol | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
695,
24,
144
]
],
[
[
695,
25,
1011
],
[
1011,
24,
144
]
],
[
[
695,
24,
543
],
[
543,
24,
144
]
],
[
[
695,
63,
1324
],
[
1324,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",... | Clozapine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a ... |
DB00738 | DB04865 | 485 | 4 | [
"DDInter1420",
"DDInter1335"
] | Pentamidine | Omacetaxine mepesuccinate | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
485,
24,
4
]
],
[
[
485,
7,
10351
],
[
10351,
46,
4
]
],
[
[
485,
18,
2849
],
[
2849,
46,
4
]
],
[
[
485,
6,
9842
],
[
9842,
46,... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Pentamidine",
"{u} (Compound) upregulates {v} (Gene)",
"ATF6"
],
[
"ATF6",
"{u} (Gene) is upregu... | Pentamidine (Compound) upregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Pentamidine (Compound) downregulates TP53BP1 (Gene) and TP53BP1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Pentamidine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated ... |
DB00023 | DB09052 | 305 | 250 | [
"DDInter127",
"DDInter220"
] | Asparaginase Escherichia coli | Blinatumomab | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
305,
24,
250
]
],
[
[
305,
24,
949
],
[
949,
63,
250
]
],
[
[
305,
24,
1236
],
[
1236,
24,
250
]
],
[
[
305,
63,
1257
],
[
1257,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blin... |
DB00352 | DB01208 | 482 | 945 | [
"DDInter1814",
"DDInter1705"
] | Tioguanine | Sparfloxacin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
482,
23,
945
]
],
[
[
482,
23,
739
],
[
739,
1,
945
]
],
[
[
482,
63,
1176
],
[
1176,
1,
945
]
],
[
[
482,
21,
28826
],
[
28826,
... | [
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Tioguanine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (... |
DB00446 | DB01611 | 597 | 1,487 | [
"DDInter351",
"DDInter893"
] | Chloramphenicol | Hydroxychloroquine | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
597,
24,
1487
]
],
[
[
597,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
597,
24,
663
],
[
663,
23,
1487
]
],
[
[
597,
24,
723
],
[
723,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side... | Chloramphenicol (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when ... |
DB00191 | DB01142 | 73 | 1,264 | [
"DDInter1447",
"DDInter593"
] | Phentermine | Doxepin | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
73,
24,
1264
]
],
[
[
73,
24,
508
],
[
508,
24,
1264
]
],
[
[
73,
6,
7390
],
[
7390,
45,
1264
]
],
[
[
73,
21,
28898
],
[
28898,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Phentermine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Doxepin (Compound)
Phentermine (Compound) c... |
DB01128 | DB13074 | 918 | 877 | [
"DDInter204",
"DDInter1110"
] | Bicalutamide | Macimorelin | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
918,
25,
877
]
],
[
[
918,
62,
112
],
[
112,
23,
877
]
],
[
[
918,
24,
1320
],
[
1320,
24,
877
]
],
[
[
918,
62,
479
],
[
479,
2... | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and E... |
DB01174 | DB11921 | 697 | 1,019 | [
"DDInter1442",
"DDInter492"
] | Phenobarbital | Deflazacort | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
697,
25,
1019
]
],
[
[
697,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
697,
24,
761
],
[
761,
24,
1019
]
],
[
[
697,
64,
629
],
[
629,
... | [
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Ruca... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and ... |
DB09052 | DB10276 | 250 | 1,624 | [
"DDInter220",
"DDInter1623"
] | Blinatumomab | Rotavirus vaccine | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
250,
25,
1624
]
],
[
[
250,
63,
322
],
[
322,
25,
1624
]
],
[
[
250,
64,
375
],
[
375,
25,
1624
]
],
[
[
250,
24,
270
],
[
270,
... | [
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Blinatumomab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pego... |
DB01281 | DB08868 | 881 | 1,011 | [
"DDInter5",
"DDInter737"
] | Abatacept | Fingolimod | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
881,
25,
1011
]
],
[
[
881,
24,
748
],
[
748,
63,
1011
]
],
[
[
881,
24,
1136
],
[
1136,
24,
1011
]
],
[
[
881,
25,
976
],
[
976,
... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Abatacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthrax... | Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Abatacept may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and... |
DB00065 | DB12267 | 581 | 1,476 | [
"DDInter923",
"DDInter233"
] | Infliximab | Brigatinib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
581,
25,
1476
]
],
[
[
581,
25,
168
],
[
168,
23,
1476
]
],
[
[
581,
25,
629
],
[
629,
24,
1476
]
],
[
[
581,
64,
1184
],
[
1184,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} m... | Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Infliximab may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interact... |
DB00197 | DB11791 | 1,324 | 785 | [
"DDInter1881",
"DDInter287"
] | Troglitazone | Capmatinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1324,
24,
785
]
],
[
[
1324,
24,
1215
],
[
1215,
23,
785
]
],
[
[
1324,
24,
868
],
[
868,
24,
785
]
],
[
[
1324,
24,
1320
],
[
1320,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and... |
DB00544 | DB06643 | 970 | 1,136 | [
"DDInter757",
"DDInter500"
] | Fluorouracil | Denosumab | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
970,
24,
1136
]
],
[
[
970,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
970,
24,
1419
],
[
1419,
24,
1136
]
],
[
[
970,
40,
132
],
[
132,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Ima... |
DB00852 | DB01170 | 1,445 | 1,150 | [
"DDInter1545",
"DDInter846"
] | Pseudoephedrine | Guanethidine | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1445,
24,
1150
]
],
[
[
1445,
6,
7390
],
[
7390,
45,
1150
]
],
[
[
1445,
63,
73
],
[
73,
24,
1150
]
],
[
[
1445,
24,
1344
],
[
1344,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} ... | Pseudoephedrine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Guanethidine (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Ps... |
DB01234 | DB08816 | 1,220 | 578 | [
"DDInter513",
"DDInter1802"
] | Dexamethasone | Ticagrelor | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1220,
24,
578
]
],
[
[
1220,
6,
4973
],
[
4973,
45,
578
]
],
[
[
1220,
21,
28762
],
[
28762,
60,
578
]
],
[
[
1220,
63,
336
],
[
336,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Dexamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Dexamethasone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and... |
DB00445 | DB00624 | 322 | 1,561 | [
"DDInter655",
"DDInter1775"
] | Epirubicin | Testosterone | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Moderate | 1 | [
[
[
322,
24,
1561
]
],
[
[
322,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
322,
24,
1687
],
[
1687,
1,
1561
]
],
[
[
322,
7,
9053
],
[
9053,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Testosterone (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol and Stanozolol (Compound) resembles Testosterone (Comp... |
DB00738 | DB06176 | 485 | 1,342 | [
"DDInter1420",
"DDInter1616"
] | Pentamidine | Romidepsin | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
485,
24,
1342
]
],
[
[
485,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
485,
24,
956
],
[
956,
24,
1342
]
],
[
[
485,
24,
1616
],
[
1616,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin... |
DB06605 | DB08827 | 1,409 | 990 | [
"DDInter108",
"DDInter1085"
] | Apixaban | Lomitapide | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
1409,
24,
990
]
],
[
[
1409,
64,
1080
],
[
1080,
1,
990
]
],
[
[
1409,
6,
8374
],
[
8374,
45,
990
]
],
[
[
1409,
21,
29215
],
[
29215,... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",
... | Apixaban may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Apixaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Apixaban (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is c... |
DB00738 | DB00934 | 485 | 413 | [
"DDInter1420",
"DDInter1124"
] | Pentamidine | Maprotiline | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
485,
24,
413
]
],
[
[
485,
63,
1302
],
[
1302,
40,
413
]
],
[
[
485,
63,
847
],
[
847,
1,
413
]
],
[
[
485,
6,
7950
],
[
7950,
4... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Maprotiline... |
DB01229 | DB08912 | 973 | 1,040 | [
"DDInter1377",
"DDInter462"
] | Paclitaxel | Dabrafenib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
973,
24,
1040
]
],
[
[
973,
6,
13478
],
[
13478,
45,
1040
]
],
[
[
973,
18,
10351
],
[
10351,
46,
1040
]
],
[
[
973,
7,
3466
],
[
3466... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B3"
],
[
"SLCO1B3",
"{u} (Gene) is bound by {v} (Compound)... | Paclitaxel (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound)
Paclitaxel (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Dabrafenib (Compound)
Paclitaxel (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Dabrafenib (Compound)
Paclitaxel (Comp... |
DB01017 | DB13142 | 1,669 | 841 | [
"DDInter1224",
"DDInter274"
] | Minocycline | Calcium glubionate anhydrous | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets. | Moderate | 1 | [
[
[
1669,
24,
841
]
],
[
[
1669,
62,
504
],
[
504,
24,
841
]
],
[
[
1669,
1,
1545
],
[
1545,
24,
841
]
],
[
[
1669,
23,
674
],
[
674,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium glubionate anhydrous"
]
],
[
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlo... | Minocycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium glubionate anhydrous
Minocycline (Compound) resembles Oxytetracycline (Compound) and Oxytetracycli... |
DB01208 | DB06176 | 945 | 1,342 | [
"DDInter1705",
"DDInter1616"
] | Sparfloxacin | Romidepsin | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
945,
25,
1342
]
],
[
[
945,
62,
112
],
[
112,
23,
1342
]
],
[
[
945,
64,
485
],
[
485,
24,
1342
]
],
[
[
945,
25,
1616
],
[
1616,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Sparfloxacin may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine ma... |
DB01098 | DB09481 | 14 | 460 | [
"DDInter1622",
"DDInter1113"
] | Rosuvastatin | Magnesium carbonate | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
14,
24,
460
]
],
[
[
14,
63,
954
],
[
954,
23,
460
]
],
[
[
14,
24,
1468
],
[
1468,
23,
460
]
],
[
[
14,
25,
1519
],
[
1519,
63,... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib an... |
DB01410 | DB09473 | 423 | 884 | [
"DDInter375",
"DDInter918"
] | Ciclesonide | Indium In-111 oxyquinoline | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Indium In 111 oxyquinoline (oxine) is a diagnostic radiopharmaceutical intended for radiolabeling of autologous leukocytes. It is composed of a 3:1 saturated complex of In-111 isotope and oxyquinoline. Indium-111 decays by isomeric transition and electron capture to cadmium-111, emitting a gamma ray that can be detecte... | Moderate | 1 | [
[
[
423,
24,
884
]
],
[
[
423,
40,
218
],
[
218,
24,
884
]
],
[
[
423,
1,
1486
],
[
1486,
24,
884
]
],
[
[
423,
63,
609
],
[
609,
24... | [
[
[
"Ciclesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indium In-111 oxyquinoline"
]
],
[
[
"Ciclesonide",
"{u} (Compound) resembles {v} (Compound)",
"Beclomethasone dipropionate"
],
[
"Beclomet... | Ciclesonide (Compound) resembles Beclomethasone dipropionate (Compound) and Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Indium In-111 oxyquinoline
Ciclesonide (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate in... |
DB01178 | DB01181 | 369 | 1,532 | [
"DDInter357",
"DDInter906"
] | Chlormezanone | Ifosfamide | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
369,
24,
1532
]
],
[
[
369,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
369,
24,
849
],
[
849,
63,
1532
]
],
[
[
369,
64,
475
],
[
475,
... | [
[
[
"Chlormezanone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Chlormezanone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Chlormezanone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Chlormezanone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine an... |
DB01097 | DB08885 | 1,377 | 363 | [
"DDInter1033",
"DDInter33"
] | Leflunomide | Aflibercept | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Major | 2 | [
[
[
1377,
25,
363
]
],
[
[
1377,
25,
1531
],
[
1531,
24,
363
]
],
[
[
1377,
24,
151
],
[
151,
63,
363
]
],
[
[
1377,
64,
58
],
[
58,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"... | Leflunomide may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/... |
DB00472 | DB00927 | 758 | 1,559 | [
"DDInter758",
"DDInter712"
] | Fluoxetine | Famotidine | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
758,
24,
1559
]
],
[
[
758,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
758,
18,
10375
],
[
10375,
57,
1559
]
],
[
[
758,
21,
28826
],
[
28... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)... | Fluoxetine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Fluoxetine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Famotidine (Compound)
Fluoxetine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
... |
DB00719 | DB01043 | 1,219 | 108 | [
"DDInter149",
"DDInter1146"
] | Azatadine | Memantine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Moderate | 1 | [
[
[
1219,
24,
108
]
],
[
[
1219,
63,
506
],
[
506,
23,
108
]
],
[
[
1219,
24,
1264
],
[
1264,
63,
108
]
],
[
[
1219,
24,
1192
],
[
1192,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Memantine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Memantine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Do... |
DB00470 | DB00559 | 530 | 152 | [
"DDInter601",
"DDInter223"
] | Dronabinol | Bosentan | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
530,
24,
152
]
],
[
[
530,
6,
6017
],
[
6017,
45,
152
]
],
[
[
530,
21,
28952
],
[
28952,
60,
152
]
],
[
[
530,
24,
98
],
[
98,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Dronabinol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Dronabinol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bosentan (Compound)
Dronabinol (Compound) causes Nightmare (Side Effect) and Nightmare (Side Effect) is caused by Bosentan (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem m... |
DB06414 | DB06605 | 655 | 1,409 | [
"DDInter703",
"DDInter108"
] | Etravirine | Apixaban | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
655,
24,
1409
]
],
[
[
655,
6,
10215
],
[
10215,
45,
1409
]
],
[
[
655,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
655,
24,
1670
],
[
167... | [
[
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Etravirine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Etravirine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Apixaban (Compound)
Etravirine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Elig... |
DB00078 | DB00176 | 1,172 | 529 | [
"DDInter898",
"DDInter770"
] | Ibritumomab tiuxetan | Fluvoxamine | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Moderate | 1 | [
[
[
1172,
24,
529
]
],
[
[
1172,
64,
20
],
[
20,
24,
529
]
],
[
[
1172,
37,
1274
],
[
1274,
63,
529
]
],
[
[
1172,
25,
1421
],
[
1421,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofe... |
DB00254 | DB08903 | 964 | 996 | [
"DDInter598",
"DDInter170"
] | Doxycycline | Bedaquiline | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
964,
24,
996
]
],
[
[
964,
6,
8374
],
[
8374,
45,
996
]
],
[
[
964,
63,
305
],
[
305,
24,
996
]
],
[
[
964,
24,
603
],
[
603,
63... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Doxycycline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Doxycycline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when... |
DB05239 | DB09046 | 866 | 1,094 | [
"DDInter425",
"DDInter1201"
] | Cobimetinib | Metreleptin | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
866,
24,
1094
]
],
[
[
866,
24,
578
],
[
578,
24,
1094
]
],
[
[
866,
63,
1213
],
[
1213,
24,
1094
]
],
[
[
866,
25,
1155
],
[
1155,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasa... |
DB00848 | DB05679 | 281 | 1,683 | [
"DDInter1044",
"DDInter1907"
] | Levamisole | Ustekinumab | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
281,
24,
1683
]
],
[
[
281,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
281,
63,
126
],
[
126,
24,
1683
]
],
[
[
281,
24,
4
],
[
4,
24... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin ma... |
DB00307 | DB15233 | 1,101 | 1,650 | [
"DDInter202",
"DDInter142"
] | Bexarotene | Avapritinib | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Moderate | 1 | [
[
[
1101,
24,
1650
]
],
[
[
1101,
24,
1478
],
[
1478,
24,
1650
]
],
[
[
1101,
63,
1257
],
[
1257,
24,
1650
]
],
[
[
1101,
23,
982
],
[
982... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegf... |
DB01148 | DB04843 | 1,128 | 1,511 | [
"DDInter738",
"DDInter1149"
] | Flavoxate | Mepenzolate | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1128,
24,
1511
]
],
[
[
1128,
24,
537
],
[
537,
24,
1511
]
],
[
[
1128,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
1128,
24,
649
],
[
649,
... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glyco... |
DB00554 | DB01105 | 1,027 | 222 | [
"DDInter1478",
"DDInter1665"
] | Piroxicam | Sibutramine | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1027,
24,
222
]
],
[
[
1027,
24,
384
],
[
384,
62,
222
]
],
[
[
1027,
62,
752
],
[
752,
23,
222
]
],
[
[
1027,
24,
723
],
[
723,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Piroxicam may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine ... |
DB09330 | DB14881 | 985 | 180 | [
"DDInter1352",
"DDInter1329"
] | Osimertinib | Oliceridine | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Major | 2 | [
[
[
985,
25,
180
]
],
[
[
985,
62,
112
],
[
112,
23,
180
]
],
[
[
985,
64,
401
],
[
401,
24,
180
]
],
[
[
985,
63,
1094
],
[
1094,
2... | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
]
],
[
[
"Osimertinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Osimertinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Osimertinib may lead to a major life threatening interaction when taken with Promethazine and Promethazine m... |
DB00532 | DB09122 | 208 | 1,613 | [
"DDInter1152",
"DDInter1409"
] | Mephenytoin | Peginterferon beta-1a | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
208,
24,
1613
]
],
[
[
208,
64,
600
],
[
600,
24,
1613
]
],
[
[
208,
62,
168
],
[
168,
24,
1613
]
],
[
[
208,
24,
267
],
[
267,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Mephenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
... | Mephenytoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezom... |
DB00738 | DB11796 | 485 | 1,612 | [
"DDInter1420",
"DDInter786"
] | Pentamidine | Fostemsavir | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
485,
24,
1612
]
],
[
[
485,
63,
1324
],
[
1324,
23,
1612
]
],
[
[
485,
64,
1101
],
[
1101,
23,
1612
]
],
[
[
485,
23,
112
],
[
112,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Pentamidine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may c... |
DB00641 | DB11796 | 467 | 1,612 | [
"DDInter1675",
"DDInter786"
] | Simvastatin | Fostemsavir | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
467,
24,
1612
]
],
[
[
467,
24,
98
],
[
98,
23,
1612
]
],
[
[
467,
63,
1324
],
[
1324,
23,
1612
]
],
[
[
467,
24,
1476
],
[
1476,
... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglit... |
DB00577 | DB00738 | 1,295 | 485 | [
"DDInter1908",
"DDInter1420"
] | Valaciclovir | Pentamidine | Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades. It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline. Valacyclovir is the L-valine ester of aciclovir. It is a member o... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1295,
24,
485
]
],
[
[
1295,
21,
28981
],
[
28981,
60,
485
]
],
[
[
1295,
63,
1555
],
[
1555,
24,
485
]
],
[
[
1295,
24,
712
],
[
712,... | [
[
[
"Valaciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Valaciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (S... | Valaciclovir (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Pentamidine (Compound)
Valaciclovir may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases wh... |
DB00627 | DB09564 | 265 | 1,296 | [
"DDInter1286",
"DDInter930"
] | Niacin | Insulin degludec | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
265,
24,
1296
]
],
[
[
265,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
265,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
265,
23,
1479
],
[
1479,
... | [
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
... | Niacin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metform... |
DB00215 | DB11057 | 1,230 | 720 | [
"DDInter388",
"DDInter1223"
] | Citalopram | Mineral oil | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1230,
24,
720
]
],
[
[
1230,
25,
927
],
[
927,
63,
720
]
],
[
[
1230,
25,
1151
],
[
1151,
24,
720
]
],
[
[
1230,
24,
477
],
[
477,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafe... | Citalopram may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Citalopram may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate int... |
DB09048 | DB09143 | 555 | 313 | [
"DDInter1284",
"DDInter1701"
] | Netupitant | Sonidegib | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
555,
25,
313
]
],
[
[
555,
64,
1478
],
[
1478,
24,
313
]
],
[
[
555,
63,
578
],
[
578,
24,
313
]
],
[
[
555,
25,
484
],
[
484,
6... | [
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may ... | Netupitant may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a m... |
DB00543 | DB00816 | 87 | 1,674 | [
"DDInter82",
"DDInter1346"
] | Amoxapine | Orciprenaline | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
87,
24,
1674
]
],
[
[
87,
25,
874
],
[
874,
24,
1674
]
],
[
[
87,
64,
1636
],
[
1636,
24,
1674
]
],
[
[
87,
21,
28921
],
[
28921,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Amoxapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephr... | Amoxapine may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Amoxapine may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a mode... |
DB05679 | DB13985 | 1,683 | 546 | [
"DDInter1907",
"DDInter1108"
] | Ustekinumab | Lutetium Lu 177 dotatate | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
1683,
24,
546
]
],
[
[
1683,
63,
66
],
[
66,
24,
546
]
],
[
[
1683,
24,
270
],
[
270,
24,
546
]
],
[
[
1683,
64,
1057
],
[
1057,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrel... |
DB11760 | DB11817 | 119 | 1,259 | [
"DDInter1742",
"DDInter165"
] | Talazoparib | Baricitinib | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
119,
25,
1259
]
],
[
[
119,
63,
949
],
[
949,
24,
1259
]
],
[
[
119,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
119,
63,
384
],
[
384,
... | [
[
[
"Talazoparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (form... | Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Talazopari... |
DB11730 | DB12301 | 351 | 907 | [
"DDInter1588",
"DDInter585"
] | Ribociclib | Doravirine | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
351,
23,
907
]
],
[
[
351,
64,
1478
],
[
1478,
23,
907
]
],
[
[
351,
24,
159
],
[
159,
62,
907
]
],
[
[
351,
63,
951
],
[
951,
2... | [
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
... | Ribociclib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may caus... |
DB00586 | DB01193 | 1,512 | 819 | [
"DDInter537",
"DDInter12"
] | Diclofenac | Acebutolol | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
1512,
24,
819
]
],
[
[
1512,
24,
887
],
[
887,
1,
819
]
],
[
[
1512,
63,
88
],
[
88,
1,
819
]
],
[
[
1512,
6,
4973
],
[
4973,
45... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Compound)
Dicl... |
DB06822 | DB10672 | 802 | 297 | [
"DDInter1812",
"DDInter417"
] | Tinzaparin | Clove | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Clove allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
802,
23,
297
]
],
[
[
802,
25,
235
],
[
235,
62,
297
]
],
[
[
802,
25,
578
],
[
578,
23,
297
]
],
[
[
802,
64,
1564
],
[
1564,
2... | [
[
[
"Tinzaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
... | Tinzaparin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Tinzaparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a minor interaction that... |
DB00477 | DB00912 | 216 | 473 | [
"DDInter363",
"DDInter1581"
] | Chlorpromazine | Repaglinide | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
216,
24,
473
]
],
[
[
216,
6,
1829
],
[
1829,
45,
473
]
],
[
[
216,
7,
4789
],
[
4789,
45,
473
]
],
[
[
216,
21,
28876
],
[
28876,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound... | Chlorpromazine (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Chlorpromazine (Compound) upregulates PPARG (Gene) and PPARG (Gene) is bound by Repaglinide (Compound)
Chlorpromazine (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by ... |
DB00289 | DB01268 | 847 | 1,151 | [
"DDInter132",
"DDInter1731"
] | Atomoxetine | Sunitinib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
847,
24,
1151
]
],
[
[
847,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
847,
21,
29269
],
[
29269,
60,
1151
]
],
[
[
847,
23,
112
],
[
112,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Atomoxetine (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Sunitinib (Compound)
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with ... |
DB00488 | DB04865 | 196 | 4 | [
"DDInter57",
"DDInter1335"
] | Altretamine | Omacetaxine mepesuccinate | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
196,
24,
4
]
],
[
[
196,
25,
770
],
[
770,
24,
4
]
],
[
[
196,
24,
496
],
[
496,
63,
4
]
],
[
[
196,
63,
66
],
[
66,
24,
4... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Altretamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[... | Altretamine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vacci... |
DB01276 | DB01285 | 123 | 708 | [
"DDInter706",
"DDInter445"
] | Exenatide | Corticotropin | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
123,
24,
708
]
],
[
[
123,
63,
455
],
[
455,
23,
708
]
],
[
[
123,
24,
659
],
[
659,
62,
708
]
],
[
[
123,
63,
245
],
[
245,
24,... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilante... |
DB00687 | DB09043 | 870 | 135 | [
"DDInter747",
"DDInter36"
] | Fludrocortisone | Albiglutide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
870,
24,
135
]
],
[
[
870,
63,
126
],
[
126,
23,
135
]
],
[
[
870,
1,
1103
],
[
1103,
23,
135
]
],
[
[
870,
24,
519
],
[
519,
24... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can... |
DB00675 | DB09118 | 888 | 1,580 | [
"DDInter1744",
"DDInter1711"
] | Tamoxifen | Stiripentol | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Major | 2 | [
[
[
888,
25,
1580
]
],
[
[
888,
24,
1409
],
[
1409,
24,
1580
]
],
[
[
888,
25,
283
],
[
283,
63,
1580
]
],
[
[
888,
63,
79
],
[
79,
... | [
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a mod... |
DB00563 | DB01197 | 663 | 1,603 | [
"DDInter1174",
"DDInter292"
] | Methotrexate | Captopril | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
663,
24,
1603
]
],
[
[
663,
24,
610
],
[
610,
1,
1603
]
],
[
[
663,
5,
11573
],
[
11573,
44,
1603
]
],
[
[
663,
6,
1829
],
[
1829,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Methotrexate (Compound) treats systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Captopril (Compound)
Methotrexate (Compound) binds... |
DB01259 | DB01611 | 392 | 1,487 | [
"DDInter1024",
"DDInter893"
] | Lapatinib | Hydroxychloroquine | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
392,
25,
1487
]
],
[
[
392,
63,
1520
],
[
1520,
25,
1487
]
],
[
[
392,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
392,
62,
1247
],
[
1247... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Prim... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Lapatinib (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)... |
DB00863 | DB01043 | 1,194 | 108 | [
"DDInter1568",
"DDInter1146"
] | Ranitidine | Memantine | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Minor | 0 | [
[
[
1194,
23,
108
]
],
[
[
1194,
6,
10215
],
[
10215,
45,
108
]
],
[
[
1194,
21,
28852
],
[
28852,
60,
108
]
],
[
[
1194,
63,
1645
],
[
16... | [
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Memantine"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Ranitidine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Memantine (Compound)
Ranitidine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Memantine (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Met... |
DB05773 | DB15233 | 1,047 | 1,650 | [
"DDInter1848",
"DDInter142"
] | Trastuzumab emtansine | Avapritinib | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1047,
25,
1650
]
],
[
[
1047,
24,
159
],
[
159,
24,
1650
]
],
[
[
1047,
63,
522
],
[
522,
24,
1650
]
],
[
[
1047,
24,
908
],
[
908,
... | [
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when tak... |
DB00081 | DB06081 | 273 | 1,046 | [
"DDInter1838",
"DDInter286"
] | Tositumomab | Caplacizumab | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
273,
25,
1046
]
],
[
[
273,
23,
539
],
[
539,
62,
1046
]
],
[
[
273,
24,
222
],
[
222,
24,
1046
]
],
[
[
273,
25,
1171
],
[
1171,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Tositumomab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Tositumomab may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutrami... |
DB11943 | DB11979 | 255 | 1,320 | [
"DDInter495",
"DDInter625"
] | Delafloxacin | Elagolix | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
255,
24,
1320
]
],
[
[
255,
63,
129
],
[
129,
24,
1320
]
],
[
[
255,
62,
372
],
[
372,
24,
1320
]
],
[
[
255,
24,
484
],
[
484,
... | [
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine and C... |
DB00209 | DB00934 | 352 | 413 | [
"DDInter1886",
"DDInter1124"
] | Trospium | Maprotiline | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
352,
24,
413
]
],
[
[
352,
24,
1302
],
[
1302,
40,
413
]
],
[
[
352,
6,
7992
],
[
7992,
45,
413
]
],
[
[
352,
21,
28880
],
[
28880,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Trospium (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Maprotiline (Compound)
Trospium (Compound) causes Angiopathy (Side Effect) and Angiopat... |
DB00934 | DB01612 | 413 | 1,637 | [
"DDInter1124",
"DDInter92"
] | Maprotiline | Amyl Nitrite | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
413,
24,
1637
]
],
[
[
413,
63,
475
],
[
475,
24,
1637
]
],
[
[
413,
24,
401
],
[
401,
24,
1637
]
],
[
[
413,
25,
593
],
[
593,
... | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prom... |
DB01100 | DB08820 | 1,568 | 1,478 | [
"DDInter1470",
"DDInter997"
] | Pimozide | Ivacaftor | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
1568,
25,
1478
]
],
[
[
1568,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1568,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
1568,
63,
543
],
[
54... | [
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Pimozide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ivacaftor"
... | Pimozide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Pimozide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may... |
DB11730 | DB14443 | 351 | 987 | [
"DDInter1588",
"DDInter1931"
] | Ribociclib | Vibrio cholerae CVD 103-HgR strain live antigen | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
351,
24,
987
]
],
[
[
351,
63,
1468
],
[
1468,
24,
987
]
],
[
[
351,
64,
1362
],
[
1362,
24,
987
]
],
[
[
351,
25,
1619
],
[
1619,
... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Ribociclib may lead to a major life threatening interaction when taken with O... |
DB00261 | DB00734 | 702 | 1,664 | [
"DDInter93",
"DDInter1605"
] | Anagrelide | Risperidone | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Major | 2 | [
[
[
702,
25,
1664
]
],
[
[
702,
25,
924
],
[
924,
40,
1664
]
],
[
[
702,
18,
5833
],
[
5833,
57,
1664
]
],
[
[
702,
21,
28787
],
[
28787,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risperidone"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u... | Anagrelide may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Anagrelide (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Risperidone (Compound)
Anagrelide (Compound) causes Dermatitis (Side Effect) and Derma... |
DB00446 | DB11799 | 597 | 627 | [
"DDInter351",
"DDInter205"
] | Chloramphenicol | Bictegravir | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
597,
24,
627
]
],
[
[
597,
24,
1362
],
[
1362,
24,
627
]
],
[
[
597,
23,
466
],
[
466,
63,
627
]
],
[
[
597,
25,
1406
],
[
1406,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Darolutamide and... |
DB01035 | DB01259 | 1,401 | 392 | [
"DDInter1524",
"DDInter1024"
] | Procainamide | Lapatinib | A derivative of procaine with less CNS action. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
1401,
25,
392
]
],
[
[
1401,
21,
28900
],
[
28900,
60,
392
]
],
[
[
1401,
62,
112
],
[
112,
23,
392
]
],
[
[
1401,
25,
918
],
[
918,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Procainamide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused... | Procainamide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Lapatinib (Compound)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when tak... |
DB00594 | DB09135 | 863 | 1,211 | [
"DDInter68",
"DDInter967"
] | Amiloride | Ioxilan | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
863,
24,
1211
]
],
[
[
863,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
863,
63,
1512
],
[
1512,
25,
1211
]
],
[
[
863,
24,
1274
],
[
1274,
... | [
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Amiloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofena... |
DB00022 | DB00333 | 268 | 576 | [
"DDInter1408",
"DDInter1166"
] | Peginterferon alfa-2b | Methadone | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
268,
24,
576
]
],
[
[
268,
63,
491
],
[
491,
23,
576
]
],
[
[
268,
24,
112
],
[
112,
62,
576
]
],
[
[
268,
24,
1362
],
[
1362,
6... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegint... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Methadone
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate disea... |
DB08816 | DB09046 | 578 | 1,094 | [
"DDInter1802",
"DDInter1201"
] | Ticagrelor | Metreleptin | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
578,
24,
1094
]
],
[
[
578,
25,
230
],
[
230,
62,
1094
]
],
[
[
578,
23,
1135
],
[
1135,
63,
1094
]
],
[
[
578,
63,
866
],
[
866,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
],
[
"Relugolix"... | Ticagrelor may lead to a major life threatening interaction when taken with Relugolix and Relugolix may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moder... |
DB00341 | DB00356 | 1,242 | 1,315 | [
"DDInter343",
"DDInter366"
] | Cetirizine | Chlorzoxazone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Moderate | 1 | [
[
[
1242,
24,
1315
]
],
[
[
1242,
21,
28787
],
[
28787,
60,
1315
]
],
[
[
1242,
74,
701
],
[
701,
24,
1315
]
],
[
[
1242,
24,
13
],
[
13,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorzoxazone"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is... | Cetirizine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Chlorzoxazone (Compound)
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate int... |
DB09291 | DB11799 | 741 | 627 | [
"DDInter1615",
"DDInter205"
] | Rolapitant | Bictegravir | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
741,
24,
627
]
],
[
[
741,
63,
578
],
[
578,
24,
627
]
],
[
[
741,
24,
982
],
[
982,
63,
627
]
],
[
[
741,
64,
1670
],
[
1670,
2... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
... | Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosi... |
DB00836 | DB04953 | 543 | 495 | [
"DDInter1088",
"DDInter708"
] | Loperamide | Ezogabine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
543,
24,
495
]
],
[
[
543,
21,
28787
],
[
28787,
60,
495
]
],
[
[
543,
24,
112
],
[
112,
23,
495
]
],
[
[
543,
63,
1494
],
[
1494,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Loperamide",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is cau... | Loperamide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ez... |
DB00619 | DB05528 | 1,419 | 1,070 | [
"DDInter909",
"DDInter1228"
] | Imatinib | Mipomersen | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1419,
25,
1070
]
],
[
[
1419,
63,
1512
],
[
1512,
25,
1070
]
],
[
[
1419,
24,
1250
],
[
1250,
64,
1070
]
],
[
[
1419,
25,
594
],
[
594... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Mipomersen
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a ma... |
DB00031 | DB01240 | 20 | 885 | [
"DDInter1764",
"DDInter657"
] | Tenecteplase | Epoprostenol | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
20,
24,
885
]
],
[
[
20,
24,
1061
],
[
1061,
1,
885
]
],
[
[
20,
23,
539
],
[
539,
62,
885
]
],
[
[
20,
24,
1512
],
[
1512,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can ... |
DB00026 | DB00488 | 1,184 | 196 | [
"DDInter94",
"DDInter57"
] | Anakinra | Altretamine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Moderate | 1 | [
[
[
1184,
24,
196
]
],
[
[
1184,
24,
139
],
[
139,
63,
196
]
],
[
[
1184,
24,
599
],
[
599,
24,
196
]
],
[
[
1184,
23,
1461
],
[
1461,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzu... |
DB00201 | DB01072 | 1,684 | 915 | [
"DDInter263",
"DDInter129"
] | Caffeine | Atazanavir | Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but ... | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Minor | 0 | [
[
[
1684,
23,
915
]
],
[
[
1684,
6,
4973
],
[
4973,
45,
915
]
],
[
[
1684,
21,
28741
],
[
28741,
60,
915
]
],
[
[
1684,
24,
1031
],
[
1031... | [
[
[
"Caffeine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atazanavir"
]
],
[
[
"Caffeine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Caffeine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Caffeine (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Atazanavir (Compound)
Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylli... |
DB00705 | DB08881 | 441 | 868 | [
"DDInter496",
"DDInter1925"
] | Delavirdine | Vemurafenib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
441,
24,
868
]
],
[
[
441,
6,
8374
],
[
8374,
45,
868
]
],
[
[
441,
21,
29015
],
[
29015,
60,
868
]
],
[
[
441,
63,
608
],
[
608,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Delavirdine (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Lidocain... |
DB08916 | DB11978 | 26 | 124 | [
"DDInter32",
"DDInter822"
] | Afatinib | Glasdegib | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
26,
24,
124
]
],
[
[
26,
24,
466
],
[
466,
62,
124
]
],
[
[
26,
63,
79
],
[
79,
24,
124
]
],
[
[
26,
24,
829
],
[
829,
63,
... | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib ... |
DB01006 | DB06414 | 300 | 655 | [
"DDInter1040",
"DDInter703"
] | Letrozole | Etravirine | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
300,
24,
655
]
],
[
[
300,
6,
8374
],
[
8374,
45,
655
]
],
[
[
300,
21,
28723
],
[
28723,
60,
655
]
],
[
[
300,
63,
1101
],
[
1101,
... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etravirine (Compound)
Letrozole (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Etravirine (Compound)
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and B... |
DB00009 | DB14357 | 1,271 | 944 | [
"DDInter56",
"DDInter347"
] | Alteplase | Chamomile | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Chamomile is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1271,
23,
944
]
],
[
[
1271,
25,
256
],
[
256,
23,
944
]
],
[
[
1271,
64,
1578
],
[
1578,
23,
944
]
],
[
[
1271,
24,
1061
],
[
1061,
... | [
[
[
"Alteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
... | Alteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Alteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a minor interaction that... |
DB00705 | DB08916 | 441 | 26 | [
"DDInter496",
"DDInter32"
] | Delavirdine | Afatinib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
441,
24,
26
]
],
[
[
441,
63,
883
],
[
883,
40,
26
]
],
[
[
441,
21,
28809
],
[
28809,
60,
26
]
],
[
[
441,
25,
124
],
[
124,
63... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Delavirdine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Afatinib (Compound)
Delavirdine may lead to a major life threatening... |
DB06643 | DB11714 | 1,136 | 1,316 | [
"DDInter500",
"DDInter610"
] | Denosumab | Durvalumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
1136,
24,
1316
]
],
[
[
1136,
63,
167
],
[
167,
24,
1316
]
],
[
[
1136,
24,
270
],
[
270,
63,
1316
]
],
[
[
1136,
24,
384
],
[
384,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.